Ralph B. Arlinghaus
#155,749
Most Influential Person Now
Ralph B. Arlinghaus's AcademicInfluence.com Rankings
Ralph B. Arlinghausbiology Degrees
Biology
#11992
World Rank
#15437
Historical Rank
Biochemistry
#2015
World Rank
#2157
Historical Rank
Download Badge
Chemistry Biology
Ralph B. Arlinghaus's Degrees
- Masters Chemistry Stanford University
- Bachelors Chemistry Stanford University
Why Is Ralph B. Arlinghaus Influential?
(Suggest an Edit or Addition)Ralph B. Arlinghaus's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. (2006) (1058)
- BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. (2003) (680)
- Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53 (2004) (555)
- Bcr‐Abl oncoproteins bind directly to activators of the Ras signalling pathway. (1994) (494)
- Tissue-resident stem cells promote breast cancer growth and metastasis. (2009) (326)
- Radiation-induced Assembly of Rad51 and Rad52 Recombination Complex Requires ATM and c-Abl* (1999) (288)
- Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia (2004) (235)
- Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. (2005) (217)
- AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia (2005) (210)
- Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia. (1994) (200)
- Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). (1998) (196)
- PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. (2013) (193)
- The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity. (1985) (178)
- Multiplexed volumetric bar-chart chip for point-of-care diagnostics (2012) (174)
- Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis. (2009) (172)
- Janus kinase 2: a critical target in chronic myelogenous leukemia. (2006) (170)
- Expression of p21ras in fresh primary and metastatic human colorectal tumors. (1985) (169)
- Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. (2003) (168)
- Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. (2002) (166)
- Jak2 is involved in c-Myc induction by Bcr-Abl (2002) (163)
- Further characterization of intracellular precursor polyproteins of Rauscher leukemia virus. (1977) (160)
- Involvement of Jak2 tyrosine phosphorylation in Bcr–Abl transformation (2001) (155)
- Biosynthesis of Rauscher leukemia viral proteins (1975) (149)
- A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia. (1996) (139)
- Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis. (2002) (138)
- Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer. (2003) (134)
- Biosynthesis of Rauscher leukemia viral proteins: presence of p30 and envelope p15 sequences in precursor polypeptides. (1976) (128)
- Jak2 inhibition deactivates Lyn kinase through the SET–PP2A–SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients (2009) (126)
- NGAL decreases E-cadherin-mediated cell-cell adhesion and increases cell motility and invasion through Rac1 in colon carcinoma cells (2009) (113)
- Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. (2003) (111)
- Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism (2008) (108)
- Janus kinase 2 regulates Bcr–Abl signaling in chronic myeloid leukemia (2010) (108)
- Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. (2013) (104)
- Serine kinase activity associated with Maloney murine sarcoma virus-124-encoded p37mos. (1985) (104)
- Common Precursor for Rauscher Leukemia Virus gp69/71, p15(E), and p12(E) (1977) (97)
- The cyclin B2 component of MPF is a substrate for the c-mosxe proto-oncogene product (1990) (94)
- Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment. (2017) (91)
- MECHANISM OF PEPTIDE BOND FORMATION IN POLYPEPTIDE SYNTHESIS. (1964) (90)
- Lipocalin 2 is required for BCR-ABL-induced tumorigenesis (2008) (90)
- Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1–BCR-ABL–JAK2 Complex (2013) (88)
- A fucose-deficient glycoprotein precursor to Rauscher leukemia virus gp69/71. (1976) (83)
- Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1 (2007) (80)
- Rearrangement in the breakpoint cluster region and the clinical course in Philadelphia-negative chronic myelogenous leukemia. (1986) (78)
- Aurora kinase-A inactivates DNA damage-induced apoptosis and spindle assembly checkpoint response functions of p73. (2012) (78)
- AMN107, a novel aminopyrimidine inhibitor of p190 Bcr‐Abl activation and of in vitro proliferation of Philadelphia‐positive acute lymphoblastic leukemia cells (2005) (78)
- "gag" polyprotein precursors of Rauscher murine leukemia virus. (1977) (75)
- c-mos proto-oncogene product is partly degraded after release from meiotic arrest and persists during interphase in mouse zygotes. (1991) (74)
- Activated c-Abl tyrosine kinase in malignant solid tumors (2008) (73)
- Relationships of lipocalin 2 with breast tumorigenesis and metastasis (2011) (71)
- Membrane-permeable dideoxyuridine 5'-monophosphate analogue inhibits human immunodeficiency virus infection. (1992) (70)
- Novel GACG-hairpin pair motif in the 5' untranslated region of type C retroviruses related to murine leukemia virus (1992) (70)
- Neutrophilic‐chronic myeloid leukemia (2002) (68)
- Chronic myelogenous leukaemia with p185BCR/ABL expression: characteristics and clinical significance (1999) (68)
- P210 Bcr-Abl interacts with the interleukin 3 receptor beta(c) subunit and constitutively induces its tyrosine phosphorylation. (1996) (63)
- Purification of large amounts of murine ribonucleic acid tumor viruses produced in roller bottle cultures. (1972) (60)
- Regulation of AML2/CBFA3 in Hematopoietic Cells through the Retinoic Acid Receptor α-Dependent Signaling Pathway* (1999) (59)
- Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients. (1987) (59)
- Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexes. (2001) (58)
- Inhibition of Bcr serine kinase by tyrosine phosphorylation (1996) (57)
- Bcr-Abl-mediated suppression of normal hematopoiesis in leukemia (2005) (56)
- Detection of BCR-ABL proteins in blood cells of benign phase chronic myelogenous leukemia patients. (1991) (56)
- P85gag-mos encoded by ts110 Moloney murine sarcoma virus has an associated protein kinase activity. (1983) (54)
- Bcr phosphorylated on tyrosine 177 binds Grb2 (1997) (53)
- A ribosome-bound intermediate in polypeptide synthesis (1963) (53)
- Identification of molecular variants of p210bcr-abl in chronic myelogenous leukemia (1987) (52)
- BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia. (2008) (52)
- Cell-free synthesis of a precursor polyprotein containing both gag and pol gene products by Rauscher murine leukemia virus 35S RNA (1978) (51)
- BCR-ABL tyrosine kinase is autophosphorylated or transphosphorylates P160 BCR on tyrosine predominantly within the first BCR exon. (1993) (51)
- Characterization of 40,000- and 25,000-dalton intermediate precursors to Rauscher murine leukemia virus gag gene products (1979) (51)
- Foot-and-mouth disease virus-induced ribonucleic acid polymerase in baby hamster kidney cells. (1967) (51)
- Cell‐penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients (2000) (50)
- Mechanism of puromycin inhibition of hemoglobin synthesis. (1962) (49)
- Selective decrease in the rate of cleavage of an intracellular precursor to Rauscher leukemia virus p30 by treatment of infected cells with actinomycin D (1976) (48)
- BCR-ABL protein expression in peripheral blood cells of chronic myelogenous leukemia patients undergoing therapy. (1994) (48)
- Tryptic peptide analysis of gag and gag-pol gene products of Rauscher murine leukemia virus (1979) (47)
- Proteins of Rauscher murine leukemia virus: resolution of a 70,000-dalton, Nonglycosylated polypeptide containing p30 peptide sequences. (1975) (46)
- Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML). (2010) (45)
- A subset of Pr65gag is nucleus associated in murine leukemia virus-infected cells (1993) (44)
- Bcr: a negative regulator of the Bcr-Abl oncoprotein (1999) (43)
- The isolation of two enzyme-ribonucleic acid complexes involved in the synthesis of foot-and-mouth disease virus ribonucleic acid. (1969) (42)
- Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model. (2001) (40)
- A selective temperature-sensitive defect in viral RNA expression in cells infected with a ts transformation mutant of murine sarcoma virus (1981) (40)
- Characterization of bcr gene products in hematopoietic cells. (1989) (40)
- Inhibition of human immunodeficiency virus type 1 infection and syncytium formation in human cells by V3 loop synthetic peptides from gp120 (1993) (39)
- Expression of epidermal growth factor receptor and associated glycoprotein on cultured human brain tumor cells (1986) (39)
- Rapid in vivo induction of HIV-specific CD8+ cytotoxic T lymphocytes by a 15-amino acid unmodified free peptide from the immunodominant V3-loop of GP120. (1992) (39)
- Studies on in vivo induction of cytotoxic T lymphocyte responses by synthetic peptides from E6 and E7 oncoproteins of human papillomavirus type 16. (1995) (39)
- Requirement of the c-mos protein kinase for murine meiotic maturation. (1990) (38)
- Inhibition of cell-free foot-and-mouth disease virus-ribonucleic acid synthesis by antibody. (1967) (38)
- BCR-ABL oncogenic transformation of NIH 3T3 fibroblasts requires the IL-3 receptor (2008) (37)
- The cell-free translation of Rauscher leukemia virus RNA into high molecular weight polypeptides. (1975) (36)
- Cells transformed by certain strains of moloney sarcoma virus contain murine p60 (1977) (35)
- Endodeoxyribonuclease activity associated with Rauscher murine leukemia virus (1981) (35)
- Tyrosine phosphorylation of P160 BCR by P210 BCR-ABL. (1993) (35)
- A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition. (2010) (34)
- Liposome-incorporated Grb2 antisense oligodeoxynucleotide increases the survival of mice bearing bcr-abl-positive leukemia xenografts. (2007) (34)
- Partial characterization of a moloney murine sarcoma virus 85,000-dalton polypeptide whose expression correlates with the transformed phenotype in cells infected with a temperature-sensitive mutant virus. (1980) (34)
- Vimentin phosphorylation by p37mos protein kinase in vitro and generation of a 50-kDa cleavage product in v-mos-transformed cells. (1989) (33)
- Further characterization of the P85gag-mos -associated protein kinase activity. (1984) (33)
- Studies on foot-and-mouth disease virus ribonucleic acid synthesis. (1966) (33)
- Preparation and application of antibodies to phosphoamino acid sequences. (2001) (31)
- Requirement of two specific tyrosine residues for the catalytic activity of Bcr serine/threonine kinase (1998) (30)
- Acute lymphoid leukemia molecular phenotype in a patient with benign-phase chronic myelogenous leukemia. (1993) (30)
- Biosynthesis of reverse transcriptase from Rauscher murine leukemia virus by synthesis and cleavage of a gag-pol read-through viral precursor polyprotein. (1978) (30)
- BCR gene expression blocks Bcr-Abl induced pathogenicity in a mouse model (2001) (29)
- BCR/ABL and leukemia. (1996) (29)
- Characterization and cell-free activity of polyribosomes isolated from baby hamster kidney cells. (1970) (29)
- Characterization of MEK1 phosphorylation by the v-Mos protein. (1995) (28)
- Inhibition of Grb2 and Crkl proteins results in growth inhibition of Philadelphia chromosome positive leukemic cells. (1997) (28)
- P210 BCR-ABL is complexed to P160 BCR and ph-P53 proteins in K562 cells. (1990) (27)
- Bcr: a negative regulator of the Bcr-Abl oncoprotein in leukemia (2002) (27)
- Studies on in vivo induction of HIV-1 envelope-specific cytotoxic T lymphocytes by synthetic peptides from the V3 loop region of HIV-1 IIIB gp 120. (1995) (27)
- Detergent-Solubilized RNA Polymerase from Cells Infected with Foot-and-Mouth Disease Virus (1967) (27)
- Electron microscopic analysis of ts1 10 Moloney mouse sarcoma virus, a variant of wild-type virus with two RNAs containing large deletions. (1983) (27)
- Recognition of mos-related proteins with an antiserum to a peptide of the v-mos gene product. (1985) (26)
- P210 Bcr-Abl interacts with the interleukin-3 beta c subunit and constitutively activates Jak2. (1997) (26)
- Identification of T-cell epitopes without B-cell activity in the first and second conserved regions of the HIV Env protein. (1991) (26)
- Hemoglobin and Polyphenylalanine Synthesis with Reticulocyte Ribosomes (1963) (26)
- Processing of the env gene products of Moloney murine leukaemia virus. (1982) (26)
- Purification of the transfer enzymes from reticulocytes and properties of the transfer reaction. (1968) (25)
- Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cells (2009) (25)
- Peptide containing the BCR oligomerization domain (AA 1-160) reverses the transformed phenotype of p210bcr–abl positive 32D myeloid leukemia cells (1998) (25)
- The c-Myc Oncoprotein Interacts with Bcr (2003) (25)
- Comparison of bcr-abl protein expression and Philadelphia chromosome analyses in chronic myelogenous leukemia patients. (1996) (25)
- Studies of polyphenylalanine synthesis with reticulocyte ribosomes (1962) (25)
- 3-Hydroxyproline, a new amino acid of collagen. (1962) (25)
- Sequences within the first exon of BCR inhibit the activated tyrosine kinases of c-Abl and the Bcr-Abl oncoprotein. (1996) (25)
- p37mos-associated serine/threonine protein kinase activity correlates with the cellular transformation function of v-mos (1986) (25)
- The role of calmodulin in cell transformation. (1983) (24)
- Mos and the cell cycle. (1997) (24)
- Identification of molecular variants of p210bcr-abl in chronic myelogenous leukemia. (1987) (24)
- Inhibition of the NADPH oxidase regulates heme oxygenase 1 expression in chronic myeloid leukemia (2012) (24)
- Cell-free synthesis of Rauscher murine leukemia virus "gag" and "gag-pol" precursor polyproteins from virion 35 S RNA in a mRNA-dependent translation system derived from mouse tissue culture cells. (1978) (24)
- S1 nuclease mapping of viral RNAs from a temperature-sensitive transformation mutant of murine sarcoma virus (1984) (24)
- The Sox4/Tcf7l1 axis promotes progression of BCR-ABL-positive acute lymphoblastic leukemia (2014) (24)
- Tyrosine kinase inhibitors induce mesenchymal stem cell-mediated resistance in BCR-ABL+ acute lymphoblastic leukemia. (2015) (24)
- Requirement of lipocalin 2 for chronic myeloid leukemia (2008) (23)
- The involvement of Bcr in leukemias with the Philadelphia chromosome. (1998) (23)
- Identification of the protein product of the c-mos proto-oncogene in mouse testes. (1988) (23)
- Temperature-sensitive viral RNA expression in Moloney murine sarcoma virus ts110-infected cells (1985) (22)
- Suppression of Murine Retrovirus Polypeptide Termination: Effect of Amber Suppressor tRNA on the Cell-Free Translation of Rauscher Murine Leukemia Virus, Moloney Murine Leukemia Virus, and Moloney Murine Sarcoma Virus 124 RNA (1980) (22)
- Signal transduction pathways in Bcr-Abl transformed cells. (2004) (22)
- Current status of the BCR gene and its involvement with human leukemia. (1991) (22)
- Cross-reactive cytotoxic T lymphocytes induced by V3 loop synthetic peptides from different strains of human immunodeficiency virus type 1. (1995) (21)
- Studies on peptides obtained from enzymic digests of collagen with evidence for the presence of an unidentified compound in this protein. (1961) (21)
- Sequence of events in the transformation process in cells infected with a temperature-sensitive transformation mutant of Moloney murine sarcoma virus. (1981) (21)
- Analysis of Philadelphia chromosome-negative BCR-ABL-positive chronic myelogenous leukemia by hypermetaphase fluorescence in situ hybridization. (1999) (21)
- Structural components of a virus of the California encephalitis complex: LaCrosse virus. (1973) (21)
- Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy (2002) (20)
- Bcr and Abl interaction: oncogenic activation of c-Abl by sequestering Bcr. (2003) (20)
- Formation and function of the active ribosome complex. (1966) (20)
- HSP90 inhibitor AUY922 induces cell death by disruption of the Bcr-Abl, Jak2 and HSP90 signaling network complex in leukemia cells (2015) (20)
- Roles of p53, NF-κB and the androgen receptor in controlling NGAL expression in prostate cancer cell lines. (2018) (20)
- Comparative tryptic peptide analysis of candidate P85gag-mos of ts110 Moloney murine sarcoma virus and P38-P23 mos gene-related proteins of wild-type virus. (1982) (20)
- STUDIES ON HEMOGLOBIN SYNTHESIS* (1964) (20)
- Somatic cell expression of the c-mos protein (1989) (20)
- POLYRIBOSOME FORMATION AND HEMOGLOBIN SYNTHESIS. (1963) (20)
- Gag-mos Polyproteins encoded by variants of the Moloney strain of mouse sarcoma virus. (1983) (20)
- Use of site-specific antipeptide antibodies to perturb the serine kinase catalytic activity of p37mos (1985) (19)
- p160 Bcr Mediates Platelet-Derived Growth Factor Activation of Extracellular Signal-Regulated Kinase in Vascular Smooth Muscle Cells (2001) (18)
- The translation products of Moloney murine sarcoma virus-124 RNA. (1980) (18)
- Moloney murine sarcoma virus encoded p37mos expressed in yeast has protein kinase activity. (1986) (17)
- The gag-mos hybrid protein of ts110 Moloney murine sarcoma virus: variation of gene expression with temperature. (1984) (17)
- BIOSYNTHESIS AND PROCESSING OF RAUSCHER LEUKEMIA VIRAL PRECURSOR POLYPROTEINS (1976) (17)
- Effects of influenza virus-specific cytotoxic T-lymphocyte responses induced by a synthetic nucleoprotein peptide on the survival of mice challenged with a lethal dose of virus. (1994) (17)
- Ribosomes from Rauscher leukemia virus-infected cells and their response to Rauscher viral RNA and polyuridylic acid. (1973) (17)
- p120 GAP requirement in normal and malignant human hematopoiesis (1993) (16)
- Tryptic peptide analyses of polypeptides generated by premature termination of cell-free protein synthesis allow a determination of the Rauscher leukemia virus gag gene order (1978) (16)
- Phosphorylation of v-mos Ser 47 by the mitotic form of p34cdc2. (1991) (16)
- Cell-free synthesis of Rauscher murine leukemia virus "gag" and "env" gene products from separate cellular mRNA species. (1979) (16)
- Inhibition of the Bcr-Abl oncoprotein by Bcr requires phosphoserine 354. (2002) (16)
- The histidine-221 to tyrosine substitution in v-mos abolishes its biological function and its protein kinase activity. (1988) (16)
- Characterization of intracellular precursor polyproteins of Moloney murine leukemia virus (1979) (15)
- BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment (2010) (15)
- The physical interactions between p37env-mos and tubulin structures. (1992) (15)
- Inhibition of v-Mos kinase activity by protein kinase A (1996) (15)
- Induction of human immunodeficiency virus-specific T cell responses in rhesus monkeys by synthetic peptides from gp160. (1993) (15)
- In vitro proteolytic cleavage of Gazdar murine sarcoma virus p65gag (1981) (15)
- Inhibition of maturation of Rauscher leukemia virus by amino acid analogs (1978) (14)
- Effects of Ectopic Expression of NGAL on Doxorubicin Sensitivity (2012) (13)
- Temperature‐dependent transmembrane potential changes in cells infected with a temperature‐sensitive moloney sarcoma virus (1984) (13)
- Inhibition of phosphorylation of p160 BCR within p210 BCR-ABL complexes during early stages of phorbol ester-induced differentiation of K562 cells. (1993) (13)
- The ts110 Moloney mouse sarcoma virus system: gag-mos gene products and cellular transformation. (1985) (12)
- Cell cycle-mediated structural and functional alteration of P85gag-mos protein kinase activity. (1990) (12)
- In vitro products of a membrane-free foot-and-mouth disease virus ribonucleic acid polymerase. (1969) (12)
- Multiple BCR‐related gene products and their proposed involvement in ligand‐induced signal transduction pathways (1992) (12)
- Evidence for involvement of the protein kinase C pathway in the activation of p37v-mos protein kinase. (1990) (12)
- P85gag-mos encoded by ts110 Moloney murine sarcoma virus: rapid at the restrictive temperature. (1983) (12)
- Incorporation of lipids into variants of Moloney sarcoma virus which produce gag-mos fusion proteins. (1984) (12)
- Chronic Myelogenous Leukemia: Molecular Approaches to Research and Therapy (1990) (12)
- Electrophoretic Characterization of Foot-and-Mouth Disease Virus-Specific Ribonucleic Acid (1969) (11)
- Temperature-sensitive splicing defect of ts110 Moloney murine sarcoma virus is virus encoded (1986) (11)
- Expression of a truncated first exon BCR sequence in chronic myelogenous leukemia cells blocks cell growth and induces cell death. (2001) (11)
- Stimulation of amino acid incorporation by Rauscher murine leukemia virus RNA in a cell-free system. (1972) (11)
- The P55 protein affected by v-mos expression is vimentin (1987) (11)
- Studies on V3‐specific cross‐reactive T‐cell responses in chimpanzees chronically infected with HIV‐1IIIB (1995) (11)
- c-Abl Activates Janus Kinase 2 in Normal Hematopoietic Cells* (2014) (10)
- Characterization of viral polyproteins in cells transformed and producing Moloney murine sarcoma virus-124. (1980) (10)
- Activation of Jak2 in patients with blast crisis chronic myelogenous leukemia: inhibition of Jak2 inactivates Lyn kinase (2013) (10)
- Carboxyamidotriazole inhibits cell growth of imatinib-resistant chronic myeloid leukaemia cells including T315I Bcr-Abl mutant by a redox-mediated mechanism. (2011) (10)
- Combination of JAK2 and HSP90 inhibitors: an effective therapeutic option in drug-resistant chronic myelogenous leukemia (2016) (10)
- Antibodies against small nuclear ribonucleoproteins immunoprecipitate complexes containing ts110 Moloney murine sarcoma virus genomic and messenger RNAs. (1986) (10)
- Further characterization of the c-mos transcript and its cell cycle specific expression in NIH3T3 cells. (1996) (10)
- P85: a gag-mos Polyprotein Encoded by ts110 Moloney Murine Sarcoma Virus (1983) (10)
- Further studies on the glycosylated gag gene products of Rauscher murine leukemia virus: identification of an N-terminal 45,000-dalton cleavage product (1983) (9)
- Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb 2-SoS complexes (2001) (9)
- Association of v-Mos with soluble vimentin in vitro and in transformed cells. (1993) (9)
- Effect of Actinomycin D on Virus-induced Ribonucleic Acid Polymerase Formation in Foot-and-Mouth Disease Virus-Infected Baby Hamster Kidney Cells (1967) (9)
- Effect of Canavanine on Murine Retrovirus Polypeptide Formation (1980) (9)
- Inhibition of c-mos protein kinase blocks mouse zygotes at the pronuclei stage. (1991) (9)
- p37(mos) encoded by the HT-1 strain of Moloney murine sarcoma virus has an associated protein kinase activity (1988) (8)
- Bcr in Vascular Smooth Muscle Cells (2001) (8)
- v-mos protein produced by in vitro translation has protein kinase activity (1990) (8)
- Expression of the v-mos gene alters a Mr 55,000 protein during acute infection by Moloney murine sarcoma virus. (1986) (8)
- Saltatory thermal denaturation of double-stranded viral RNAs. (1978) (8)
- Use of antipeptide antibodies to probe the catalytic activity of p37v-mos. (1990) (8)
- The presence of the Rb c-box peptide in the cytoplasm inhibits p210bcr-abl transforming function (1999) (8)
- The mos proto‐oncogene product: Its role in oocyte maturation, metaphase arrest, and neoplastic transformation (1992) (7)
- Inhibition of ribonucleic acid methylation in the foot-and-mouth disease virus-infected host cell. (1967) (7)
- Site of foot-and-mouth disease virus-ribonucleic acid synthesis and some properties of its double-stranded ribonucleic acid. (1968) (7)
- Vaccination with leukemia cells expressing cell-surface-associated GM-CSF blocks leukemia induction in immunocompetent mice (2006) (7)
- Presence of retrovirus in the B95-8 Epstein-Barr virus-producing cell line from different sources (1984) (7)
- A cAMP-independent serine/threonine kinase activity is associated with the mos sequences of ts110 Moloney murine sarcoma virus-encoded P85gag-mos. (1985) (7)
- Factor-dependent binding of Rauscher leukemia virus RNA to ribosomes. (1972) (7)
- Kinase domain mutants of Bcr enhance Bcr-Abl oncogenic effects (2008) (7)
- Effect of varying the KC1 and MgCl2 concentration on the enzymic and nonenzymic binding of phenylalanyl-RNA to reticulocyte ribosomes. (1968) (7)
- Expression of bcr–abl mRNA in individual chronic myelogenous leukaemia cells as determined by in situ amplification (2001) (6)
- Requirement of lipocalin 2 for hematopoietic and solid tumor malignancies. (2009) (6)
- Evidence of a Functional Interaction between Serine 3 and Serine 25 Mos Phosphorylation Sites (1998) (6)
- The structural relatedness of the virus core proteins of Rauscher and Moloney murine leukaemia virus. (1980) (6)
- Polyadenylic acid in the genomic RNA of mengovirus (1976) (6)
- [153] Aminoacyl transfer enzymes from reticulocytes (1968) (6)
- Precursor polyproteins of Moloney murine leukemia virus. (1979) (5)
- Use of helper T cell-inducing peptides from conserved regions in HIV-1 env in a noncovalent mixture with a CTL-inducing V3-loop peptide for in vivo induction of long-lasting systemic CTL response. (1994) (5)
- Differential effects of tumor promoters on P210bcr-abl expression. (1989) (5)
- A novel 53 kDa protein complexed with P210bcr-abl in human chronic myelogenous leukemia cells. (1988) (5)
- Acetylethyleneimine in the preparation of inactivated food-and-mouth disease vaccines. (1967) (5)
- Vaccination with Leukemia Cells Expressing Cell-Surface-Associated GM-CSF Blocks Leukemia Induction in Immunocompetent Mice. (2004) (5)
- TRANSLATION PRODUCTS OF THE 124 STRAIN OF MOLONEY MURINE SARCOMA VIRUS (Mo-MuSV): CHARACTERIZATION OF A 23,000 DALTON CANDIDATE ‘src’ GENE PRODUCT (1980) (5)
- Characterization of virus-specified proteins present in NRK cells infected with a temperature-sensitive transformation mutant of Moloney murine sarcoma virus. (1980) (5)
- Abstract LB-109: BCR-ABL1 kinase activity but not its expression is dispensable for Ph+ quiescent stem cell survival which depends on the PP2A-controlled Jak2 activation and is sensitive to FTY720 treatment (2011) (4)
- AMN107, Novel Aminopyrimidine Inhibitor of Bcr-Abl, Is Significantly More Potent Than Imatinib Mesylate Against Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Cells. (2004) (4)
- Essential role of c-mos in eggs: Reduced fertility and ovarian neoplasm in antisense mos transgenic mice (1997) (4)
- Novel circular forms of mengovirus-specific double-stranded RNA detected by electron microscopy. (1982) (4)
- Attachment of avidin-coupled spheres to linear and circular forms of mengovirus double-stranded RNA (1981) (4)
- Effective Concentration of a Multikinase Inhibitor within Bone Marrow Correlates with In Vitro Cell Killing in Therapy-Resistant Chronic Myeloid Leukemia (2016) (4)
- Binding of retrovirus-associated protein kinase and proteins to Staphylococcus aureus. (1982) (4)
- Temperature-dependent cytocidal effects of Moloney murine sarcoma virus. (1986) (4)
- v-mos proteins encoded by myeloproliferative sarcoma virus and its ts159 mutant (1992) (4)
- Isolation and partial characterization of a 55,000-dalton protein induced in cells transformed by the ml strain of Moloney murine sarcoma virus. (1980) (3)
- Preparation and Application of Polyclonal and Monoclonal Sequence‐Specific Anti‐Phosphoamino Acid Antibodies (2003) (3)
- RNA polymerase complexes from mengovirus infected cells (2005) (3)
- Properties of Moloney sarcoma virus-specific p60 and its detection in transformed cells. (1976) (3)
- Erratum: Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia (Cancer Research (January 15, 2004) (672-677)) (2004) (3)
- A Subset ofPr65gag IsNucleus Associated inMurine Leukemia Virus-Infected Cells (1993) (3)
- Oncogenes and their involvement in chronic myelogenous leukemia (1987) (3)
- Effect of Foot-and-Mouth Disease Virus on Protein Synthesis and Ribonucleic Acid Polymerase Activity at Various Temperatures (1970) (3)
- Stable polypeptides associated with the 250S mengovirus-induced RNA polymerase structure (2005) (3)
- Elevated level of cyclin D1 in mos-transformed cells. (1998) (3)
- Erratum: Somatic cell expression of the c-mos protein (Oncogene (1989)4, No.11, 1307-1315) (1990) (2)
- Biosynthesis of Murine Leukemia Virus Membrane Proteins and their Assembly into Virus Particles (1978) (2)
- Evidence for somatic cell expression of the c-mos protein [corrected]. (1989) (2)
- Jak2 Phosphorylates Tyr 177 of Bcr-Abl Activating the Ras and PI-3 Kinase Pathways and Maintains Functional Levels of Bcr-Abl in Chronic Myelogenous Leukemia. (2009) (2)
- Bcr-Abl regulates c-Myc expression in chronic myelogenous leukemia through a Bcr-Abl/Jak2 network of proteins involving Gab2, PI-3 kinase, NF-κB and GSK3β (2006) (2)
- Changes in protein and nucleic acid metabolism in baby hamster kidney cells infected with foot-and-mouth disease virus (2005) (2)
- SelectivekillingofoncogenicallytransformedcellsthroughaROS- mediated mechanism by b-phenylethyl isothiocyanate (2006) (2)
- Evidence for interaction between v-Mos and a p34cdc2 isoform, p35cdk. (1992) (2)
- UseofSite-Specific Antipeptide Antibodies toPerturb theSerine Kinase Catalytic Activity ofp37mos (1985) (2)
- Bcr-Abl-Mediated Suppression of Normal Hematopoiesis in Chronic Myeloid Leukemia: Involvement of a Modified Form of NGAL. (2005) (2)
- A novel HIV vaccine strategy. (1990) (2)
- Reversion of thermosensitive splicing defect of Moloney murine sarcoma virus ts110 by oversplicing of viral RNA (1990) (2)
- Identification of a new viral protein containing CAp30 and NCp10 sequences in murine and feline leukemia retroviruses (1995) (2)
- Rooting into the Soil, a Model for the Role of Sox4 in Leukemia (2008) (2)
- Cross-reactive T-cell proliferative responses to V3 peptides corresponding to different geographical HIV-1 isolates in HIV-seropositive individuals (1996) (2)
- Vaccines against tumor antigens. (1989) (2)
- Tyrosine Phosphorylation of P 160 BCR by P 210 BCR-ABL (2003) (2)
- Independence in Chronic Myelogenous Leukemia Imatinib Mesylate Resistance Through BCR-ABL (2004) (1)
- Combined Targeting of BCR-ABL and JAK2 with ABL and JAK2 Inhibitors Is Effective Against CML Patients' Leukemic Stem/Progenitor Cells. (2010) (1)
- Dual tel-abl fusion in a PH-negative chronic myeloid leukemia patient (2000) (1)
- Evidence that small phenylalanine peptides bound to ribosomes are attached to sRNA. (1968) (1)
- Jak2: A Potential Therapeutic Target for Chronic Myelogenous Leukemia (CML). (2006) (1)
- Purification of Large Amounts of Murine Ribonucleic Acid Tumor Viruses Produced in Roller Bottle Cultures (1972) (1)
- Inhibition of viral mos gene-expression in transformed-cells restricts cell-cycle progression through g1-phase and g2-phase. (1992) (1)
- Role of BCR in Down-Modulation of BCR-ABL Oncogenicity in CML (2008) (1)
- Lipocalin-2 Promotes Obesity-Induced Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment (2016) (1)
- Disruption of the Bcr-Abl/Jak2/HSP90 Network Complex Leading to Induction of Apoptosis in Drug-Resistant CML Cells by a New Compound WP1193 (2008) (1)
- Activated c-Abl in FUS1 haploinsufficient non-small cell lung carcinoma (2005) (1)
- Further characterization of the in vitro products generated by proteolytic cleavage of Gazdar murine sarcoma virus p65gag. (1985) (1)
- Jak2 Regulates Lyn Tyrosine Kinase through Interference with the SET/PP2A/Shp1 Pathway and Inhibition of Jak2 Induced Apoptosis in BCR-ABL+ Imatinib-Sensitive and Resistant CML Cells. (2007) (1)
- The Role of c-Abl in Jak2 Activation in IL-3-Dependent Cells (2011) (1)
- SOX4 gene expression in human leukemic and benign hematopoietic cells (2006) (1)
- p 160 Bcr Mediates Platelet-Derived Growth Factor Activation of Extracellular Signal – Regulated Kinase in Vascular Smooth Muscle Cells (2001) (1)
- WITHDRAWN: Requirement of lipocalin 2 in breast cancer. (2009) (1)
- Abstract 2007: Differential roles of BCL-XL and BCL-2 in protecting mitochondria against oxidative stress in CML cells (2012) (0)
- The ATP Competitor INNO-406 (NS-187) Inhibits Proliferation and Survival of Mouse Cells Expressing Several Immatinib Mesylate Resistant Bcr/Abl Mutants and Cells from CML Patients. (2006) (0)
- Vaccination with Leukemia Cell Expression Membrane Bound GM-CSF Overcomes the Host Immunosuppression Induced by Leukemia (2008) (0)
- Two RNA polymerase complexes involved in cell-free synthesis of foot-and-mouth disease virus RNA. (1969) (0)
- Advances in Brief Bcr and Abl Interaction : Oncogenic Activation of c-Abl by Sequestering Bcr 1 (2003) (0)
- The biological effects of antisense mos expression in fibroblasts. (1997) (0)
- SiNuclease Mapping ofViral RNAsfromaTemperature-Sensitive Transformation MutantofMurineSarcoma Virus (1984) (0)
- Sarcoma Virus tsllO by Oversplicing of Viral RNA (0)
- Jak2 Regulates Bcr-Abl In CD34+ Cells From Imatinib Mesylate-Resistant CML Patients. (2010) (0)
- Transplantation of splenic T-cells from mice vaccinated with lethally-irradiated leukemia cells expressing cell surface GM-CSF prevents leukemia. (2006) (0)
- The WD40-Repeats of Ahi-1 Oncogene Critical for Protein Interaction Between Ahi-1 and BCR-ABL Modulates Imatinib-Induced Apoptosis In BCR-ABL-Transduced Cells (2010) (0)
- MECHANISM OF PEPTIDE BOND FORMA TION IN POLYPEPTIDE SYNTHESIS* BY RALPH ARLINGHAUS,t (2003) (0)
- Oncogenic Transformation of NIH 3T3 Fibroblasts by BCR-ABL Oncoprotein Requires the IL-3 Receptor. (2007) (0)
- A LIMITING LAW RELATING THE SIZE AND SHAPE OF PROTEIN MOLECULES TO THEIR COMPOSITION (0)
- Enhanced Jak2 Activation Correlates with β Chain Expression Leading to Phosphorylation of Tyrosine 177 of Bcr-Abl. (2009) (0)
- Dual inhibition of JAK2V617F and BCR-ABLT315I by a novel class of non-ATP competitive kinase inhibitors (2007) (0)
- Comparative tryptic peptide analysis of P85gag-mos of Mo-MuSV ts-110 and the P38-P23 mos-related products of wild-type virus. (1983) (0)
- Roles of BCL‐2/BCL‐XL in regulation of BCR‐ABL‐induced mitochondrial oxidative stress (2012) (0)
- Synthetic HTLV-III peptide compositions and their use. (1987) (0)
- Interfering Breast Cancer Metastasis by Blocking NGAL Function (2011) (0)
- Detection and quantitation of BCR-ABL transcripts using a comprehensive quantitative rtpcr analysis system for minimal residual disease in CML patients (2000) (0)
- Antiretroviral Action of Interferon (1981) (0)
- Polyadenylic AcidintheGenomicRNA ofMengovirus (1976) (0)
- Expression of the Abl SH2 domain activates the c-Abl tyrosine kinase and induces morphological transformation (1997) (0)
- phosphorylation.of Bcr serine kinase by tyrosine (2013) (0)
- NovelGACG-Hairpin PairMotif inthe5'Untranslated Region of TypeC Retroviruses Related toMurineLeukemia Virus (1992) (0)
- Expression and biological significance of type I insulin-like growth factor receptor tyrosine kinase in chronic myeloid leukemia (2008) (0)
- Analysis of PllO * " " " " * ' Tyrosine Protein Kinase Activity in Various Subtypes of Philadelphia Chromosome-positive Cells from Chronic Myelogenous Leukemia Patients 1 (2006) (0)
- Polypeptides associated with the 250 S mengovirus-induced RNA polymerase structure (2005) (0)
- Methode de dosage de substances affectant la transformation mediee par bcr-abl (1994) (0)
- Somatic-cell expression of the mos protooncogene is cell-cycle regulated - highest RNA expression in the g2 phase. (1993) (0)
- P 85 gagmos encoded by tsllO Moloney murine sarcoma virus has an associated protein kinase activity ( gag-mos phosphoprotein / phosphotransferase / retrovirus transforming protein ) (0)
- ORIGINAL ARTICLE Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia (2011) (0)
- Formation of mengovirus-like particles in cell-free extracts from virus-infected cells. (1974) (0)
- Abstract 1124: Expression of the lipocalin 2 oncogene in the development of smoking-associated and Kras mutant lung adenocarcinoma (2016) (0)
- Erratum: Chronic myelogenous leukaemia with p185(BCR/ABL) expression: Characteristics and clinical significance (British Journal of Haematology (1999) 107 (581-586)) (2000) (0)
- Bcr strongly inhibits the tumorigenic effects of Bcr-Abl but mutant Bcr proteins lack inhibitory effects and enhance Bcr-Abl oncogenic effects. (2007) (0)
- Inhibition of Human Immunodeficiency Virus Type 1 Infection and Syncytium Formation in Human Cells by V 3 Loop Synthetic Peptides from gpl 20 (0)
- K562-R As a Model to Study Jak2 in a Non Bcr-Abl Addicted Cell Line (2011) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Ralph B. Arlinghaus?
Ralph B. Arlinghaus is affiliated with the following schools:
